Fulcrum Therapeutics Target of Unusually High Options Trading (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was the target of unusually large options trading on Wednesday. Stock investors acquired 30,075 call options on the stock. This represents an increase of 1,522% compared to the typical daily volume of 1,854 call options.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. National Bank of Canada FI boosted its position in shares of Fulcrum Therapeutics by 869.6% during the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after purchasing an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Fulcrum Therapeutics by 66.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock valued at $112,000 after purchasing an additional 4,766 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Fulcrum Therapeutics by 26.5% during the third quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock worth $118,000 after buying an additional 6,926 shares in the last quarter. Profund Advisors LLC acquired a new position in Fulcrum Therapeutics in the second quarter worth approximately $68,000. Finally, American Century Companies Inc. increased its holdings in shares of Fulcrum Therapeutics by 13.2% in the second quarter. American Century Companies Inc. now owns 104,371 shares of the company’s stock valued at $647,000 after buying an additional 12,167 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Analyst Upgrades and Downgrades

FULC has been the topic of several recent analyst reports. HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $17.00 to $4.00 in a report on Friday, September 13th. Cantor Fitzgerald cut Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Leerink Partnrs cut Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Finally, Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Price Performance

FULC stock opened at $3.27 on Friday. Fulcrum Therapeutics has a 1-year low of $2.87 and a 1-year high of $13.70. The firm has a fifty day moving average price of $6.75 and a two-hundred day moving average price of $7.36. The firm has a market cap of $203.24 million, a price-to-earnings ratio of -2.01 and a beta of 2.21.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.93. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 8.28%. The company had revenue of $80.00 million for the quarter, compared to analyst estimates of $80.00 million. During the same quarter last year, the business earned ($0.38) earnings per share. As a group, analysts expect that Fulcrum Therapeutics will post -0.28 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.